In the 2026 CUNY study, HDAP2 penetrated the blood-retinal barrier, localized to retinal ganglion cells, and prevented mitochondrial loss after optic nerve crush — treated nerves held nearly threefold higher mitochondrial density than untreated ones, and RGC survival improved across all retinal regions.

Panacea Bio Chem · Compound Investigation

Compound investigation · Mitochondria-targeted peptides

HDAP2 — the high-density aromatic peptide that tells mitochondria to hold.

Q: What is HDAP2?

HDAP2 is a high-density aromatic peptide (Biotin-dArg-Phe-Phe-dArg-amide) designed by a CUNY research team to support mitochondrial membrane integrity under cellular stress. It is a mitochondria-targeted research peptide.

Q: What is the HDAP2 sequence?

Biotin-dArg-Phe-Phe-dArg-amide: an N-terminal biotin tag, D-arginines flanking two phenylalanines, C-terminal amide. The sequence is published in MacNeil et al., Neuroscience 598:187-199 (2026).

Q: Who invented HDAP2?

HDAP2 was designed by MacNeil, Arain, Mentor, Garcia-Marin and Birk (York College / CUNY Graduate Center). Therapeutic applications are patented by The Research Foundation, CUNY (inventors MacNeil and Birk). Panacea Bio Chem investigates the peptide and claims no invention.

Q: Why is Panacea Bio Chem investigating HDAP2?

Because it is exactly the class of molecule Panacea's platforms exist for: a small, delicate, terminally amidated aromatic peptide whose value lives or dies with its formulation, preservation and delivery.

HDAP2 (Biotin-dArg-Phe-Phe-dArg-amide) is a mitochondria-targeted peptide built by a CUNY research team to keep mitochondrial membranes intact under cellular stress. In their 2026 optic-nerve study it crossed the blood-retinal barrier, reached the retinal ganglion cells, and stopped the mitochondria from disappearing. Panacea Bio Chem investigates this peptide.

Original research: MacNeil MA, Arain S, Mentor W, Garcia-Marin V, Birk A — Neuroscience 598:187–199 (2026) · DOI 10.1016/j.neuroscience.2026.01.045 · full text free at PMC13080697

In one paragraph: HDAP2 is a tiny five-part peptide — a biotin tag, two D-arginines, two phenylalanines, an amide cap — designed to walk into stressed cells and hold their mitochondria in place. After optic nerve crush in mice, daily HDAP2 kept mitochondrial density in injured nerves at nearly threefold the untreated level, close to uninjured controls, and retinal ganglion cell survival improved across every retinal region measured. It prevents the loss; it does not claim to undo it.

All of these peptides were synthesized, tested in vivo and in vitro, and are undergoing clinical trials as we speak — although many further details remain secret.

The molecule

HDAP stands for high-density aromatic peptide. The CUNY team designed it to carry a dense aromatic core between charged arginine wings — a shape that reads like a bracket holding a photograph:

Biotin–dArg–Phe–Phe–dArg–amide. Sequence as published in MacNeil et al. 2026 (synthesized for the study by GenScript).

Three design choices carry the whole molecule: the D-arginines (cationic wings that drive cell entry and resist proteases), the Phe-Phe aromatic core (the "high-density" heart that sits in mitochondrial membranes), and the terminal amide cap (the small C-terminal closure that small signalling peptides have used for half a billion years — the same feature that makes APGWamide work).

What it was built to do — and what the study showed

Mitochondrial dysfunction is one of the earliest drivers of retinal ganglion cell death after optic nerve injury. HDAP2 was designed for that exact pressure point: support mitochondrial membrane integrity while the cell is under stress. The 2026 CUNY study (optic nerve crush in C57BL/6 mice, both sexes, n = 31) measured it end to end:

Measured	HDAP2 result (daily, systemic)
Blood-retinal barrier	Penetrated; localized to retinal ganglion cells and mitochondrial-rich retinal layers
RGC survival	Significantly improved vs saline — across central, midperipheral and peripheral retina
Mitochondrial density in crushed axons (TEM)	Nearly 3-fold higher than untreated; approached uninjured controls
Mitochondrial morphology	Unchanged across groups — HDAP2 prevents loss, it does not rescue damaged organelles
Structurally intact axons	Numerically higher density — less ultrastructural degeneration

The authors' conclusion: HDAP2 limits mitochondrial loss and attenuates neuronal degeneration after optic nerve crush — a candidate for protecting CNS projection neurons by maintaining mitochondrial stability after axonal injury.

Classic neuron histology — soma, dendrites and axon of the nerve-cell class HDAP2 protects — Panacea Bio Chem — The stage: a nerve cell's soma, dendrites and axon. Classic neuron histology, public domain (Wikimedia Commons).

Citation: MacNeil MA, Arain S, Mentor W, Garcia-Marin V, Birk A. "The mitochondria-targeted peptide HDAP2 reduces mitochondrial loss and retinal ganglion cell degeneration after optic nerve injury." Neuroscience 598:187–199, 2026. PubMed 41633465 · free full text.

The class it belongs to — and the theories around it

HDAP2 sits in the aromatic-cationic family of mitochondria-targeted peptides — the lineage that runs through elamipretide (SS31) and its relatives: small, cell-penetrating, drawn to mitochondria by charge and held there by aromatic contact with the membrane. The working theory of the whole class is that a peptide small enough to walk through tissue and lipophilic-cationic enough to sit in a membrane can protect the organelle that decides whether a stressed cell lives. HDAP2's contribution to that theory is density: a high aromatic load per residue, and a prevention-first profile — hold the membrane, never lose the mitochondrion.

Credit where credit is due

HDAP2 was designed and published by Mark A. MacNeil, Sheherbano Arain, William Mentor, Virginia Garcia-Marin and Alexander Birk — Department of Biology, York College of the City University of New York, and the CUNY Graduate Center. Therapeutic applications of HDAP2 are patented by The Research Foundation, CUNY (inventors MacNeil and Birk); at publication the patent holders reported no commercial relationships related to it.

Panacea Bio Chem investigates HDAP2 and claims no invention. Everything we know about it comes from their published work, and it is linked in full on our references page.

Why Panacea Bio Chem investigates it

Because HDAP2 is exactly the kind of molecule this house exists for: a small, delicate, terminally amidated aromatic peptide whose entire value lives or dies with its formulation, preservation and delivery. A peptide that prevents mitochondrial loss is only as good as its own survival between synthesis and the cell. That is the part of the problem Panacea works on — keeping delicate peptides intact, cold-chain or not, and delivering them in a state worth measuring.

Why this investigation sits at Panacea

The container that wakes the molecule. A peptide this delicate is carried in the Lyoprester — vacuum-sealed, argon-locked, and it reconstitutes itself at the moment of use, not before.

The peptides, on sale. The estate's research peptides are on the shelf at the Peptourbillons shop — the same preservation chain, end to end.

One chain, no handoffs. Synthesis in Syntheseract, formulation computed with Dicoias Ψ, preservation by the low-temperature stack, delivery in the Lyoprester cartridge. Count the handoffs — there are none.

Frequently asked

What is HDAP2? A high-density aromatic peptide (Biotin-dArg-Phe-Phe-dArg-amide) designed by a CUNY research team to support mitochondrial membrane integrity under cellular stress — a mitochondria-targeted research peptide.

What is the HDAP2 sequence? Biotin-dArg-Phe-Phe-dArg-amide — published in MacNeil et al., Neuroscience 598:187–199 (2026).

What does HDAP2 do? In the 2026 study it crossed the blood-retinal barrier, reached retinal ganglion cells, and prevented mitochondrial loss after optic nerve crush — nearly threefold higher mitochondrial density than untreated nerves, with RGC survival improved across all retinal regions.

Who invented HDAP2? MacNeil, Arain, Mentor, Garcia-Marin and Birk at CUNY; therapeutic applications are patented by The Research Foundation, CUNY. Panacea Bio Chem investigates the peptide and claims no invention. More on the FAQ page.